Phase 3 trial results for melanoma treatment

Detailed results from a phase 3 trial on melanoma, a type of skin cancer, support the potential of a personalized therapy developed by Moderna and Merck. The trial, called INTerpath-001, involved 1,137 patients with high-risk melanoma that had been surgically removed.

Therapy reduces recurrence risk

In the trial, a combination of autogene intismeran, an experimental messenger RNA therapy tailored to each patient, and Merck’s immunotherapy drug Keytruda reduced the relative risk of melanoma recurrence or death by 42% compared to Keytruda alone. After two years, 82.2% of patients receiving the combination therapy were alive without recurrence, compared to 70% in the group treated with Keytruda alone.

Personalized manufacturing challenges

Intismeran is made based on the genetic features of each patient’s tumor, allowing the selection of specific mutations and the production of messenger RNA that codes for up to 34 neoantigens. This customized manufacturing process involves challenges such as sequencing, target selection, quality control, and timely delivery, which must be managed within treatment timeframes. Production costs, available capacity, and reimbursement methods will be key factors in the treatment’s commercial success.

Merck’s financial performance

Merck reported $18.1 billion in global revenue for the third quarter of 2026, a 5% increase compared to the same period in the previous year. Keytruda and its formulation Keytruda Qlex generated $8.6 billion in quarterly sales, a 6% increase. Merck highlighted the INTerpath-001 trial as a major advance in its research efforts.

Future research and commercial goals

The partnership between Merck and Moderna aims to expand Keytruda’s use in post-surgery treatment and diversify Moderna’s portfolio beyond infectious disease vaccines. However, the companies must still prove their ability to produce and distribute the treatment effectively. The research program continues in other cancer types, but the melanoma results do not guarantee similar success in those trials. Next steps include regulatory approval, ongoing patient monitoring, and developing an economically viable system for personalized manufacturing.